For the year ending 2025-12-31, REGN made $14,342,900K in revenue. $4,590,300K in net income. Net profit margin of 32.00%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue from contract with customer | 14,342,900 | 14,202,000 | 13,117,200 | 12,172,900 |
| Research and development | 5,850,200 | 5,132,000 | 4,439,000 | 3,592,500 |
| Acquired in-process research and development | 124,100 | 101,000 | 186,100 | 255,100 |
| Selling, general, and administrative | 2,700,000 | 2,954,400 | 2,631,300 | 2,115,900 |
| Cost of goods sold and of collaboration and contract manufacturing-Product | 1,140,800 | 1,087,300 | 932,100 | 800,000 |
| Cost of goods sold and of collaboration and contract manufacturing-Collaborationand Contract Manufacturing | 959,900 | 883,200 | 883,700 | 760,400 |
| Other operating (income) expense, net | 10,000 | -53,400 | 2,100 | 89,900 |
| Total expenses | 10,765,000 | 10,211,300 | 9,070,100 | 7,434,000 |
| Income from operations | 3,577,900 | 3,990,700 | 4,047,100 | 4,738,900 |
| Other income (expense), net | 1,696,600 | 844,400 | 225,200 | 179,300 |
| Interest expense | 43,800 | 55,200 | 73,000 | 59,400 |
| Total other income (expense) | 1,652,800 | 789,200 | 152,200 | 119,900 |
| Income before income taxes | 5,230,700 | 4,779,900 | 4,199,300 | 4,858,800 |
| Income tax expense | 725,800 | 367,300 | 245,700 | 520,400 |
| Net income | 4,504,900 | 4,412,600 | 3,953,600 | 4,338,400 |
| Unrealized gain on debt securities | 83,000 | 73,600 | 158,200 | -213,600 |
| Loss on foreign currency translation | - | - | -300 | - |
| Gain (loss) on foreign currency translation | 2,400 | -600 | - | - |
| Unrealized gain on cash flow hedges | - | 0 | - | 1,000 |
| Comprehensive income | 4,590,300 | 4,485,600 | 4,111,500 | 4,125,800 |
| Net income per share - basic (in dollars per share) | 43.07 | 40.9 | 37.05 | 40.51 |
| Net income per share - diluted (in dollars per share) | 41.48 | 38.34 | 34.77 | 38.22 |
| Weighted average shares outstanding - basic (in shares) | 104,600,000 | 107,900,000 | 106,700,000 | 107,100,000 |
| Weighted average shares outstanding - diluted (in shares) | 108,600,000 | 115,100,000 | 113,700,000 | 113,500,000 |
REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN)